H1N1 백신 시장 : 유형별, 항원 유형별, 제조 플랫폼별, 제형별, 최종 사용자별, 유통 채널별, 연령층별 시장 예측(2026-2032년)

The H1N1 Vaccines Market is projected to grow by USD 3.13 billion at a CAGR of 5.13% by 2032.

H1N1 vaccines remain a core pillar of global influenza prevention because influenza A(H1N1)pdm09, the virus that emerged during the 2009 pandemic, continues to circulate as a seasonal influenza strain. The World Health Organization estimates seasonal influenza causes 290,000 to 650,000 respiratory deaths each year worldwide, reinforcing the public health value of updated annual vaccination programs.

Demand for H1N1 vaccines is shaped by national immunization recommendations, pandemic preparedness stockpiles, strain-selection decisions, and manufacturing capacity across egg-based, cell-based, and recombinant platforms. For decision-makers, the H1N1 vaccine landscape is not only a seasonal procurement category but also a strategic readiness asset for health security, supply continuity, and high-risk population protection.

Transformative Shifts in the H1N1 Vaccine Landscape

The H1N1 vaccines landscape is shifting from reactive pandemic response toward continuous preparedness, faster strain adaptation, and more resilient production networks. Since the 2009 H1N1 pandemic, which the U.S. Centers for Disease Control and Prevention estimates caused 151,700 to 575,400 respiratory and cardiovascular deaths globally in its first year, governments have strengthened surveillance-linked vaccine planning and emergency procurement frameworks.

Manufacturers are also responding to demand for faster scale-up and diversified production. Egg-based vaccines remain widely used, while cell-culture and recombinant technologies reduce dependence on egg supply chains and can accelerate response timelines. At the same time, broader use of quadrivalent and high-dose influenza vaccines in selected populations has raised expectations for better-matched, risk-targeted immunization strategies.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing H1N1 vaccine strategy through faster analysis of viral surveillance data, antigenic drift patterns, adverse-event monitoring, and demand forecasting. AI-supported bioinformatics can help researchers screen candidate antigens and compare viral sequences at scale, complementing the WHO Global Influenza Surveillance and Response System that informs biannual vaccine strain recommendations.

Commercially, AI can improve batch planning, cold-chain allocation, and regional demand prediction during seasonal peaks or outbreak alerts. However, its impact depends on validated datasets, transparent model governance, and regulatory acceptance. For industry leaders, AI is best positioned as an evidence-acceleration layer rather than a substitute for clinical evaluation, strain-selection committees, and pharmacovigilance systems.

Key Regional Insights

Asia-Pacific is a high-priority region due to large populations, dense urban centers, cross-border travel, and strong influenza surveillance investments in countries such as China, Japan, South Korea, India, and Australia. Japan and Australia maintain mature seasonal vaccination infrastructure, while India and China continue to expand domestic vaccine capabilities and public health reach, supporting broader H1N1 vaccine availability during seasonal and preparedness-driven campaigns.

North America benefits from established annual influenza vaccination recommendations, advanced manufacturing capacity, and strong public-private pandemic preparedness mechanisms. Europe is shaped by European Medicines Agency oversight, national immunization schedules, and procurement coordination across EU member states, creating a structured pathway for updated influenza vaccines. Latin America continues to expand seasonal influenza campaigns, with Brazil and Mexico playing important roles in regional procurement and surveillance. The Middle East is influenced by health security planning, international mobility, and mass-gathering preparedness, while Africa faces rising preparedness needs where urbanization, limited cold-chain reach, and variable healthcare access increase the importance of targeted H1N1 vaccine availability.

Key Group Insights

ASEAN countries present strong long-term relevance as governments strengthen immunization systems and prepare for respiratory disease outbreaks in highly connected urban and travel corridors. The GCC is influenced by health security planning, centralized procurement, and seasonal risks linked to mass gatherings and international mobility, making timely H1N1 vaccine access an important component of public health readiness.

The European Union emphasizes regulatory harmonization, pharmacovigilance, and coordinated strain-based approvals, supporting predictable influenza vaccine access across member states. BRICS countries combine large population needs with growing domestic manufacturing capability, particularly in China, India, Brazil, and Russia. G7 nations remain influential in funding influenza research, pandemic preparedness, surveillance modernization, and advanced vaccine technology. NATO countries increasingly view vaccine supply resilience as part of broader biosecurity, civil preparedness, and continuity planning for health systems.

Key Country Insights

The United States remains one of the most influential H1N1 vaccine environments because the CDC recommends annual influenza vaccination for everyone aged six months and older, with emphasis on older adults, pregnant people, young children, and individuals with chronic conditions. Canada follows a similarly structured seasonal influenza approach through national guidance and provincial delivery systems, while Mexico and Brazil rely on public campaigns that prioritize high-risk populations, healthcare workers, and outbreak preparedness.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain national immunization programs supported by strong regulatory oversight, pharmacovigilance, and influenza surveillance systems, while Russia combines domestic production capacity with national vaccination campaigns. China and India are essential to future H1N1 vaccine access due to population scale, expanding manufacturing ecosystems, and evolving adult immunization infrastructure. Japan, Australia, and South Korea represent advanced Asia-Pacific markets with strong surveillance, higher public awareness, established seasonal influenza vaccine channels, and rapid policy responsiveness during respiratory disease threats.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing flexibility, validated strain-update workflows, and supply-chain redundancy across active pharmaceutical ingredients, vials, syringes, adjuvants, and cold-chain logistics. Diversifying across egg-based, cell-based, and recombinant platforms can reduce operational exposure and improve readiness for sudden H1N1 demand spikes.

Organizations should also invest in evidence generation for high-risk groups, real-world effectiveness studies, AI-enabled demand forecasting, and interoperable pharmacovigilance systems. Partnerships with national public health agencies, regional procurement bodies, and surveillance networks will be critical to aligning production decisions with confirmed epidemiological signals rather than speculative demand.

Research Methodology

This executive assessment is grounded in secondary research from recognized public health and regulatory sources, including the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization agencies, and peer-reviewed influenza vaccine literature. The analysis focuses on verified epidemiology, vaccination policy, strain surveillance, technology pathways, and procurement dynamics.

The methodology emphasizes triangulation across public health recommendations, regulatory guidance, disease burden estimates, and technology adoption trends. Market interpretation avoids unsupported forecasts and instead evaluates structural drivers such as seasonal influenza mortality, post-2009 H1N1 surveillance, production platform diversification, regional immunization infrastructure, and pandemic preparedness priorities.

Conclusion

H1N1 vaccines continue to occupy a strategic position within the global influenza prevention ecosystem. Although H1N1 is now part of seasonal influenza circulation, its pandemic history ensures that governments, manufacturers, and healthcare systems treat vaccine readiness as a matter of both routine prevention and emergency response.

The strongest opportunities will emerge for organizations that combine scientific credibility, manufacturing agility, regional access strategies, and data-driven decision-making. As surveillance systems, AI tools, and next-generation vaccine platforms mature, the H1N1 vaccine landscape will increasingly reward preparedness, transparency, and measurable public health impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. H1N1 Vaccines Market, by Type

• 7.1. Monovalent H1N1 Vaccine
• 7.2. Trivalent Influenza Vaccine (TIV)
• 7.3. Quadrivalent Influenza Vaccine (QIV)
• 7.4. Combination Vaccine

8. H1N1 Vaccines Market, by Antigen Type

• 8.1. Inactivated
• 8.2. Live Attenuated

9. H1N1 Vaccines Market, by Manufacturing Platform

• 9.1. Cell-Culture Based Manufacturing
• 9.2. Egg Based Manufacturing
• 9.3. Recombinant Protein Manufacturing

10. H1N1 Vaccines Market, by Dosage Form

• 10.1. Multi-Dose Vials
• 10.2. Pre-Filled Syringes

11. H1N1 Vaccines Market, by End User

• 11.1. Clinics
• 11.2. Hospitals
• 11.3. Public Health Centers

12. H1N1 Vaccines Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. H1N1 Vaccines Market, by Age Group

• 13.1. Adults
• 13.2. Children

14. H1N1 Vaccines Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. H1N1 Vaccines Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. H1N1 Vaccines Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Adimmune Corporation
• 18.3. AstraZeneca PLC
• 18.4. Bharat Biotech International Limited
• 18.5. CSL Limited
• 18.6. Daiichi Sankyo Company, Limited
• 18.7. GC Biopharma
• 18.8. GlaxoSmithKline PLC
• 18.9. Hualan Biological Vaccine Inc.
• 18.10. Inovio Pharmaceuticals
• 18.11. Merck & Co., Inc.
• 18.12. Moderna, Inc.
• 18.13. Novavax, Inc.
• 18.14. Panacea Biotec Ltd.
• 18.15. Pfizer Inc.
• 18.16. Sanofi S.A.
• 18.17. Serum Institute of India Pvt. Ltd.
• 18.18. Sinovac Biotech Ltd.
• 18.19. Zydus Group